{"organizations": [], "uuid": "eb70f433003060948d76bc221ce1118d26e91c9a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180116.html", "section_title": "Archive News &amp; Video for Tuesday, 16 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/buzz-eiger-biopharma-abandons-blood-pres/buzz-eiger-biopharma-abandons-blood-pressure-drug-after-trial-failure-idUSL3N1PB468", "country": "US", "domain_rank": 408, "title": "BUZZ-Eiger BioPharma: Abandons blood pressure drug after trial failure", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.053, "site_type": "news", "published": "2018-01-16T21:42:00.000+02:00", "replies_count": 0, "uuid": "eb70f433003060948d76bc221ce1118d26e91c9a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/buzz-eiger-biopharma-abandons-blood-pres/buzz-eiger-biopharma-abandons-blood-pressure-drug-after-trial-failure-idUSL3N1PB468", "ord_in_thread": 0, "title": "BUZZ-Eiger BioPharma: Abandons blood pressure drug after trial failure", "locations": [], "entities": {"persons": [{"name": "akankshita mukhopadhyay", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "** Drug developer’s shares fall 44.4 pct at $8.90 premarket\n** Top pct loser among all U.S.-listed stocks premarket\n** Says it would stop developing its drug to treat pulmonary arterial hypertension (PAH), a type of high blood pressure, after it failed a mid-stage study\n** The drug did not show improvement in PAH - the study’s main goal\n** PAH occurs when the arteries of the lungs constrict, forcing the heart to work harder and potentially leading to its failure\n** However, the company says it would continue testing the drug, ubenimex, for lymphedema, a blockage of fluid causing swelling in the arms and legs\n** Up to Friday’s close, stock had risen 36.17 pct in the past twelve months (Reporting by Akankshita Mukhopadhyay in Bengaluru)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-16T21:42:00.000+02:00", "crawled": "2018-01-17T19:58:12.000+02:00", "highlightTitle": ""}